Stevenage, UK, July 6 2012 – Stevenage Bioscience Catalyst (SBC), the UK’s first
open innovation bioscience campus, announces today that its inaugural Open
Innovation Summit will take place on November 15 2012 in Stevenage, UK.
Showcasing open innovation programmes from across the bioscience industry and
at SBC, this focused event will show how open innovation is adding value to drug
discovery and development.
The Summit will also feature insightful speeches from leading commentators in the
field, focusing on real experiences and successful approaches to open innovation. It
will be of interest to biotechnology and pharmaceutical business leaders, academic
researchers, entrepreneurs, investors and government decision-makers.
Registration details will be announced shortly.
'This meeting is about making open innovation work in real life, as exemplified by the
recent news that Cambridge University will be locating some research activities here
in order to access drug development expertise' said Dr Martino Picardo, CEO of
Stevenage Bioscience Catalyst. 'We are looking forward to hosting this meeting,
where delegates will hear the latest results, real-life examples and good practice in
this important area, and will also be updated on SBC's open innovation initiatives in
areas such as screening and biomarkers. We hope to make the Open Innovation
Summit an important annual event
Join the open innovation debate at SBC:
www.stevenagecatalyst.com
LinkedIn - Stevenage Bioscience Catalyst Open Innovation Group
twitter - @SteBioCat
For more information, please contact:
Stevenage Bioscience Catalyst
Martino Picardo, CEO +44 (0)1438 906906
Emma Palmer Foster, Strategic Communications Consultant +44 (0)7880 787185
comms@stevenagecatalyst.com
About Stevenage Bioscience Catalyst
Stevenage Bioscience Catalyst is the UK’s first open innovation bioscience campus,
pioneering a unique culture to drive early stage drug discovery and development. It is
backed by £38m of funding from its founding partners – GlaxoSmithKline, the Wellcome
Trust, the Department for Business, Innovation and Skills, the Technology Strategy Board
and the former East of England Development Agency. Consisting of an Incubator, an
Accelerator and a Hub, covering 60,000 sq ft of laboratory, office and networking space, the
independent facility is expected to house a range of companies, from virtual and start-up
firms to those which are more established, as well as other organisations. Located on the
GlaxoSmithKline Stevenage site, Stevenage Bioscience Catalyst is in the unique position of
operating in proximity to the expertise and resources of a major pharmaceutical company,
close to both London and Cambridge. For more information, please go to
www.stevenagecatalyst.com.
About Open Innovation
Firms using Open Innovation (OI) combine their own R&D with externally sourced ideas and
expertise. OI is characterised by highly effective use of connections and networks to
exchange knowledge and ideas, external partners being involved at all stages of product
development, equitable win-win business relationships, and new business models to
maximise the value of intellectual property and other assets. Examples in various sectors
have shown that the benefits of OI include reduced time to market for new products and
services, access to new markets, improved innovation success rates and increased profits.
SBC will promote use of Open Innovation within the life sciences sector, connecting SMEs
with an active network consisting of GlaxoSmithKline and its other stakeholders, academia,
charities, other businesses and funding bodies. The term ‘Open Innovation’ and related
research into its practice has been developed extensively by Professor Henry Chesbrough,
Executive Director of the Program in Open Innovation at the University of California,
Berkeley (http://openinnovation.berkeley.edu).
About GlaxoSmithKline
GSK aims to improve the quality of human life by enabling people to do more, feel better and
live longer. This mission gives us the purpose to develop innovative medicines and products
that help millions of people around the world. Every hour we spend more than £300,000
(US$562,000) in our search for new medicines that can make a difference to patients.We
are one of the pharmaceutical industry leaders, with an estimated seven per cent of the
world's pharmaceutical market and one of the few companies researching both medicines
and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS,
tuberculosis and malaria. As a company with a firm foundation in science, we have a flair for
research and a track record of turning that research into powerful, marketable drugs.
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary
improvements in human and animal health. It supports the brightest minds in biomedical
research and the medical humanities. The Trust’s breadth of support includes public
engagement, education and the application of research to improve health. It is independent
of both political and commercial interests. www.wellcome.ac.uk
About the Department for Business, Innovation and Skills
The Department for Business, Innovation and Skills (BIS) is building a dynamic and
competitive UK economy by: creating the conditions for business success; promoting
innovation, enterprise and science; and giving everyone the skills and opportunities to
succeed. To achieve this it will foster world-class universities and promote an open global
economy. BIS - Investing in our future.
About the Technology Strategy Board
The Technology Strategy Board works to drive economic growth by making the UK a global
leader in innovation. Established by the government, the Technology Strategy Board helps
business to innovate faster and more effectively than would otherwise be possible. It uses its
expertise, connections and funding to enable collaborations and partnerships between
businesses, researchers and government, and to help business to create innovative
products and services which will meet market needs, tackle the challenges of our time and
build the economy of tomorrow. www.innovateuk.org
About EEDA
EEDA's mission was to improve the economy of the East of England through helping
businesses prosper, supporting people to be the best they can and breathing new life into
places. Working with others it helped improve the lives of thousands of people with
investments that will continue to have an impact for decades to come. EEDA worked across
the six counties of Bedfordshire, Cambridgeshire, Essex, Hertfordshire, Norfolk and Suffolk ,
and unitary authorities of Central Bedfordshire, Bedford , Luton, Peterborough , Southend-
on-Sea and Thurrock. In the Emergency Budget of 22 June 2010, the government confirmed
its intention to abolish all regional development agencies and replace them with Local
Enterprise Partnerships. EEDA closed in March 2012.